ClinicalTrials.gg
Active, not recruitingNCT04078295Updated Oct 13, 2026

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

A Phase 1/2 interventional study of E7389-LF and Nivolumab in Solid Neoplasms, sponsored by Eisai Co., Ltd.. Active, not recruiting at 19 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Eisai Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The primary purpose of the study is to evaluate safety and tolerability of E7389 liposomal formulation (E7389-LF) in combination with nivolumab and to determine the recommended Phase 2 dose (RP2D) in Phase 1b part and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in each tumor type in Phase 2 part.

02

Conditions studied

  • Solid Neoplasms

Browse trials for

Keywords

  • E7389 liposomal formulation
  • Nivolumab
  • Neoplasms
  • Solid Tumor
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 125 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Phase 1b part only: Participants with advanced, nonresectable, or recurrent solid tumor for which no alternative standard therapy or no effective therapy exists (participants who will be the candidate of treatment by nivolumab monotherapy as standard therapy is acceptable)
  2. Phase 2 part only: Participants with a confirmed diagnosis of nonresectable gastric cancer (GC), esophageal cancer (EGC) or small cell lung cancer (SCLC) who showed disease progression based on investigator's assessment during or after chemotherapy (second-line chemotherapy for GC) and did not receive any other systemic chemotherapy to advanced/recurrent disease
  3. Participants who meet the following criteria for ; Phase 1b part: Participants who have accessible tumors for biopsy and agree to tumor biopsy for pre- and post-treatment of study drug (If a pre-treatment biopsy cannot be obtained due to safety issue, then an archival tumor tissue sample may be submitted.) Phase 2 part: Participants who have accessible tumors for biopsy and agree with tumor biopsy for pre and post treatment of study drug (As an alternative to pre-treatment biopsy, tumor tissue sample taken from recurrent or advanced disease may be submitted). However, if the sponsor and the investigator discuss and agree in advance, and the participants agree to submission of archival tumor tissue, then these participants are eligible regardless of accessible tumors, and consent to biopsy is not necessary
  4. of greater than or equal to (>=) 12 weeks
  5. -Performance Status (ECOG-PS) 0-1
  6. Phase 2 part only: At least one based on 1.1 (Lesions that have had radiotherapy or loco-regional therapies must show evidence of progressive disease to be deemed a measurable lesion)

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with meningeal carcinomatosis
  2. Participants with brain or subdural or invasion are not eligible
  3. Active, known, or suspected disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Phase 1b, Cohort 1: E7389-LF Dose 1 + Nivolumab Dose 1

    Participants will receive E7389-LF (intravenous) Dose 1 and nivolumab (intravenous) Dose 1 on specified days.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 1b, Cohort 2: E7389-LF Dose 2 + Nivolumab Dose 1

    Participants will receive E7389-LF (intravenous) Dose 2 and nivolumab (intravenous) Dose 1 on specified days.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 1b, Cohort 3: E7389-LF Dose 3 + Nivolumab Dose 2

    Participants will receive E7389-LF (intravenous) Dose 3 and nivolumab (intravenous) Dose 2 on specified days.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 1b, Cohort 4: E7389-LF Dose 4 + Nivolumab Dose 2

    Participants will receive E7389-LF (intravenous) Dose 4 and nivolumab (intravenous) Dose 2 on specified days.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 2, Cohort-1: E7389-LF + Nivolumab

    Participants with gastric cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 2, Cohort-2: E7389-LF + Nivolumab

    Participants with esophageal cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.

    Drug: E7389-LF · Drug: Nivolumab

  • Experimental
    Phase 2, Cohort-3: E7389-LF + Nivolumab

    Participants with small lung cancer will receive RP2D of E7389-LF (intravenous) and nivolumab (intravenous) determined in Phase 1b part.

    Drug: E7389-LF · Drug: Nivolumab

Interventions

  • DrugE7389-LF

    E7389-LF Intravenous infusion.

  • Nivolumab Intravenous infusion.

    Also known as: ONO-4538

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants with Dose Limiting Toxicities (DLTs)

    DLTs are defined as study drug related adverse events (AEs). Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE 5.0).

    Time frame: Baseline up to Cycle 1 (Cycle length is equal to [=] up to 28 days)

  2. Phase 2: ORR

    ORR is defined as the percentage of participants who have best overall response of complete response (CR) or partial response (PR). The ORR will be assessed by investigator based on response evaluation criteria in solid tumors (RECIST) version 1.1.

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

Secondary outcomes

  1. Phase 1b and Phase 2: Number of Participants With AEs and Serious Adverse Events (SAEs)

    Time frame: Up to 30 days after the last dose of study drug or before initiating post anti-cancer treatment, whichever shorter (up to approximately 79 months)

  2. Phase 1b and Phase 2: Number of Participants With Markedly Abnormal Laboratory Evaluations

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

  3. Phase 1b and Phase 2: Number of Participants With Markedly Abnormal Vital Signs

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

  4. Phase 1b and Phase 2: Number of Participants With Clinically Abnormal 12-lead Electrocardiogram (ECG)

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

  5. Phase 1b and Phase 2: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

  6. Phase 1b and 2: Number of Participants With Clinically Significant Abnormal Physical Examination Findings

    Time frame: Baseline up to End of Treatment (Up to approximately 79 months)

  7. Phase 1b and Phase 2, Cmax: Maximum Observed Plasma Concentration of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  8. Phase 1b and Phase 2: Serum Concentration of Nivolumab

    Time frame: Up to Cycle 13 (each Cycle length = up to 28 days)

  9. Phase 1b and Phase 2, Tmax: Time to Maximum Observed Plasma Concentration (Cmax) of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  10. Phase 1b and Phase 2, AUC: Area Under the Plasma Concentration-time Curve Over Time From 0 to Last Measurable Concentration of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  11. Phase 1b and Phase 2, T1/2: Terminal Phase Elimination Half-life of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  12. Phase 1b and Phase 2, CL: Total Body Clearance of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  13. Phase 1b and Phase 2, Vd: Volume of Distribution of E7389-LF

    Time frame: Phase 1b, Cycle 1 Day 1: 0 to 24 hours, Cycle 1 Days 4 and 8; Phase 2, Cycle 1 Days 1 and 8 (Cycle length = up to 28 days)

  14. Phase 2: Progression-Free Survival (PFS)

    PFS is defined as the time from the date of the first administration of drug to the date of the first documentation of disease progression or death due to any cause, whichever comes first. The PFS will be assessed by investigator based on RECIST version 1.1.

    Time frame: From the first does of the study drug up to the first documentation of disease progression or death due to any cause, whichever comes first (up to approximately 79 months)

07

Study locations

19 sites
  • Eisai Trial Site #13
    Nagoya, Aichi-ken, Japan
  • Eisai Trial Site #18
    Kashiwa, Chiba, Japan
  • Eisai Trial Site #2
    Kashiwa, Chiba, Japan
  • Eisai Trial Site #14
    Matsuya, Ehime, Japan
  • Eisai Trial Site #4
    Kurume, Fukuoka, Japan
  • Eisai Trial Site #11
    Akashi, Hyōgo, Japan
  • Eisai Trial Site #15
    Yokohama, Kanaga, Japan
  • Eisai Trial Site #3
    Sendai, Miyagi, Japan
  • Eisai Trial Site #6
    Chuo Ku, Osaka, Japan
  • Eisai Trial Site #8
    Chuo Ku, Osaka, Japan
  • Eisai Trial Site #5
    Osakasa, Osaka, Japan
  • Eisai Trial Site #7
    Sakai C, Osaka, Japan
  • Eisai Trial Site #17
    Suita, Osaka, Japan
  • Eisai Trial Site #19
    Kitaadachi-gun, Saitama, Japan
  • Eisai Trail Site #16
    Sunto-g, Shizuo, Japan
  • Eisai Trial Site #1
    Chuo Ku, Tokyo, Japan
  • Eisai Trial Site #10
    Koto-Ku, Tokyo, Japan
  • Eisai Trial Site #9
    Wakayama, Wakaya, Japan
  • Eisai Trial Site #12
    Kōtoku, Japan
08

References and documents

Publications

  • Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, Tsushima T, Hirao M, Tsuda M, Hino K, Yamamoto N, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Ooki A. Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort. BJC Rep. 2024 Sep 4;2(1):66. doi: 10.1038/s44276-024-00066-6. PubMed 39516370 ↗
  • Kawazoe A, Yamamoto N, Sugimoto N, Kawakami H, Oshima T, Yamaguchi K, Hino K, Hirao M, Kurokawa Y, Kawakami T, Tsuda M, Hara H, Kaname S, Matsuoka D, Otake Y, Yasuda K, Takase T, Takashima S, Semba T, Muro K. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clin Cancer Res. 2024 Apr 1;30(7):1264-1272. doi: 10.1158/1078-0432.CCR-23-1768. PubMed 38295160 ↗

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Mar 2027, 90 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 90 months is above that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2019
First posted
Sep 6, 2019
StartActual
Sep 5, 2019
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04078295
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Sep 6, 2019
Start date
Sep 5, 2019
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion